Baxter Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER HLTHCARE, and when can generic versions of BAXTER HLTHCARE drugs launch?
BAXTER HLTHCARE has two hundred and eighteen approved drugs.
There are sixteen US patents protecting BAXTER HLTHCARE drugs. There are two tentative approvals on BAXTER HLTHCARE drugs.
There are thirty-seven patent family members on BAXTER HLTHCARE drugs in thirteen countries and three hundred supplementary protection certificates in fifteen countries.
Summary for Baxter Hlthcare
| International Patents: | 37 |
| US Patents: | 16 |
| Tradenames: | 330 |
| Ingredients: | 129 |
| NDAs: | 218 |
Drugs and US Patents for Baxter Hlthcare
Expired US Patents for Baxter Hlthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare | BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-005 | Jan 27, 2003 | 6,310,094*PED | ⤷ Try a Trial |
| Baxter Hlthcare | BREVIBLOC | esmolol hydrochloride | INJECTABLE;INJECTION | 019386-003 | Aug 15, 1988 | 5,017,609*PED | ⤷ Try a Trial |
| Baxter Hlthcare | IFEX/MESNEX KIT | ifosfamide; mesna | INJECTABLE;INJECTION | 019763-004 | Oct 10, 1992 | 4,882,452 | ⤷ Try a Trial |
| Baxter Hlthcare | MESNEX | mesna | INJECTABLE;INTRAVENOUS | 019884-001 | Dec 30, 1988 | 4,220,660 | ⤷ Try a Trial |
| Baxter Hlthcare Corp | ZOSYN IN PLASTIC CONTAINER | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 050750-002 | Feb 24, 1998 | 8,133,883 | ⤷ Try a Trial |
| Baxter Hlthcare | SUPRANE | desflurane | LIQUID;INHALATION | 020118-001 | Sep 18, 1992 | 4,762,856*PED | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAXTER HLTHCARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 10 mg/mL, 250 mL infusion bags and 20 mg/mL, 100 mL infusion bags | ➤ Subscribe | 2014-01-31 |
| ➤ Subscribe | Inhalation | 99.90% | ➤ Subscribe | 2008-09-11 |
International Patents for Baxter Hlthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 243654 | ⤷ Try a Trial |
| Brazil | 112022015170 | ⤷ Try a Trial |
| China | 105288650 | ⤷ Try a Trial |
| Japan | 2018052991 | ⤷ Try a Trial |
| Israel | 208956 | ⤷ Try a Trial |
| Brazil | PI0905080 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Baxter Hlthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2465580 | SPC/GB21/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: CABOTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING CABOTEGRAVIR SODIUM.; REGISTERED: UK EU/1/20/1481 (NI) 20201221; UK PLGB 35728/0055-57 20201221 |
| 1948158 | 300810 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS HET SACUBITRIL VALSARTAN NATRIUMZOUTCOMPLEX, IE. TRINATRIUM (3-((LS,3R)-1-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-METHYL-2'-(PENTANOYL(2"-(TETRAZOL-5-YLAAT)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT) HEMIPENTAHYDRAAT; REGISTRATION NO/DATE: EU/1/15/1058 20151123 |
| 1870100 | 122012000047 | Germany | ⤷ Try a Trial | PRODUCT NAME: DABIGATRAN ETEXILAT MESILAT = 3-((2-((4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO)-METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO)-PROPIONSAEURE-ETHYLESTER-METHANSULFONAT; REGISTRATION NO/DATE: EU/1/08/442/001-008 20080318 |
| 0788360 | 04C0014 | France | ⤷ Try a Trial | PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426 |
| 2563920 | CR 2019 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
